199 related articles for article (PubMed ID: 27548442)
1. Culture and Drug Profiling of Patient Derived Malignant Pleural Effusions for Personalized Cancer Medicine.
Ruiz C; Kustermann S; Pietilae E; Vlajnic T; Baschiera B; Arabi L; Lorber T; Oeggerli M; Savic S; Obermann E; Singer T; Rothschild SI; Zippelius A; Roth AB; Bubendorf L
PLoS One; 2016; 11(8):e0160807. PubMed ID: 27548442
[TBL] [Abstract][Full Text] [Related]
2. Human lung adenocarcinoma cell cultures derived from malignant pleural effusions as model system to predict patients chemosensitivity.
Roscilli G; De Vitis C; Ferrara FF; Noto A; Cherubini E; Ricci A; Mariotta S; Giarnieri E; Giovagnoli MR; Torrisi MR; Bergantino F; Costantini S; Fenizia F; Lambiase M; Aurisicchio L; Normanno N; Ciliberto G; Mancini R
J Transl Med; 2016 Feb; 14():61. PubMed ID: 26928703
[TBL] [Abstract][Full Text] [Related]
3. Up-regulation of pro-angiogenic factors and establishment of tolerance in malignant pleural effusions.
Lieser EA; Croghan GA; Nevala WK; Bradshaw MJ; Markovic SN; Mansfield AS
Lung Cancer; 2013 Oct; 82(1):63-8. PubMed ID: 23948549
[TBL] [Abstract][Full Text] [Related]
4. Characterization and drug sensitivity profiling of primary malignant mesothelioma cells from pleural effusions.
Szulkin A; Otvös R; Hillerdal CO; Celep A; Yousef-Fadhel E; Skribek H; Hjerpe A; Székely L; Dobra K
BMC Cancer; 2014 Sep; 14():709. PubMed ID: 25253633
[TBL] [Abstract][Full Text] [Related]
5. Patient-derived cell models as preclinical tools for genome-directed targeted therapy.
Lee JY; Kim SY; Park C; Kim NK; Jang J; Park K; Yi JH; Hong M; Ahn T; Rath O; Schueler J; Kim ST; Do IG; Lee S; Park SH; Ji YI; Kim D; Park JO; Park YS; Kang WK; Kim KM; Park WY; Lim HY; Lee J
Oncotarget; 2015 Sep; 6(28):25619-30. PubMed ID: 26296973
[TBL] [Abstract][Full Text] [Related]
6. [Relationship between BRCA1 mRNA expression in tumor cells from malignant effusions and chemosensitivity to cisplatin in patients with metastatic malignant effusions].
Qian XP; Liu BR; Jiang M; Hu J; Yu LX; Wang LF; Hu WJ; Zou ZY
Zhonghua Zhong Liu Za Zhi; 2011 Jun; 33(6):457-60. PubMed ID: 21875488
[TBL] [Abstract][Full Text] [Related]
7. [Clinical Assessment of Chemosensitivity Test in Xeno-free Culture of Autologous
Malignant Effusion Cells from Patients with Advanced Lung Adenocarcinoma].
Chen L; Yang S; Jiang J; Zhang Y; Feng H; Cao J; Ge X; Xie W
Zhongguo Fei Ai Za Zhi; 2016 Sep; 19(9):584-9. PubMed ID: 27666547
[TBL] [Abstract][Full Text] [Related]
8. Feasibility Technique of Low-passage
Vinayanuwattikun C; Prakhongcheep O; Tungsukruthai S; Petsri K; Thirasastr P; Leelayuwatanakul N; Chanvorachote P
Anticancer Res; 2019 Dec; 39(12):6981-6988. PubMed ID: 31810970
[TBL] [Abstract][Full Text] [Related]
9. Ex vivo modelling of drug efficacy in a rare metastatic urachal carcinoma.
Mäkelä R; Arjonen A; Härmä V; Rintanen N; Paasonen L; Paprotka T; Rönsch K; Kuopio T; Kononen J; Rantala JK
BMC Cancer; 2020 Jun; 20(1):590. PubMed ID: 32576176
[TBL] [Abstract][Full Text] [Related]
10. Identification of anti-tumour biologics using primary tumour models, 3-D phenotypic screening and image-based multi-parametric profiling.
Sandercock AM; Rust S; Guillard S; Sachsenmeier KF; Holoweckyj N; Hay C; Flynn M; Huang Q; Yan K; Herpers B; Price LS; Soden J; Freeth J; Jermutus L; Hollingsworth R; Minter R
Mol Cancer; 2015 Jul; 14():147. PubMed ID: 26227951
[TBL] [Abstract][Full Text] [Related]
11. Interventions to treat malignant pleural effusions.
Lenker A; Mayer DK; Bernard SA
Clin J Oncol Nurs; 2015 Oct; 19(5):501-4. PubMed ID: 26414568
[TBL] [Abstract][Full Text] [Related]
12. Personalized in vitro cancer models to predict therapeutic response: Challenges and a framework for improvement.
Morgan MM; Johnson BP; Livingston MK; Schuler LA; Alarid ET; Sung KE; Beebe DJ
Pharmacol Ther; 2016 Sep; 165():79-92. PubMed ID: 27218886
[TBL] [Abstract][Full Text] [Related]
13. Chemosensitivity testing of human tumors using a microplate adenosine triphosphate luminescence assay: clinical correlation for cisplatin resistance of ovarian carcinoma.
Andreotti PE; Cree IA; Kurbacher CM; Hartmann DM; Linder D; Harel G; Gleiberman I; Caruso PA; Ricks SH; Untch M
Cancer Res; 1995 Nov; 55(22):5276-82. PubMed ID: 7585588
[TBL] [Abstract][Full Text] [Related]
14. Anticancer effect of tetrandrine on primary cancer cells isolated from ascites and pleural fluids.
Liu B; Wang T; Qian X; Liu G; Yu L; Ding Y
Cancer Lett; 2008 Sep; 268(1):166-75. PubMed ID: 18495333
[TBL] [Abstract][Full Text] [Related]
15. Mast cells mediate malignant pleural effusion formation.
Giannou AD; Marazioti A; Spella M; Kanellakis NI; Apostolopoulou H; Psallidas I; Prijovich ZM; Vreka M; Zazara DE; Lilis I; Papaleonidopoulos V; Kairi CA; Patmanidi AL; Giopanou I; Spiropoulou N; Harokopos V; Aidinis V; Spyratos D; Teliousi S; Papadaki H; Taraviras S; Snyder LA; Eickelberg O; Kardamakis D; Iwakura Y; Feyerabend TB; Rodewald HR; Kalomenidis I; Blackwell TS; Agalioti T; Stathopoulos GT
J Clin Invest; 2015 Jun; 125(6):2317-34. PubMed ID: 25915587
[TBL] [Abstract][Full Text] [Related]
16. 3D Culture as a Clinically Relevant Model for Personalized Medicine.
Fong ELS; Toh TB; Yu H; Chow EK
SLAS Technol; 2017 Jun; 22(3):245-253. PubMed ID: 28277923
[TBL] [Abstract][Full Text] [Related]
17. Feasibility study of in vitro drug sensitivity assay of advanced non-small cell lung adenocarcinomas.
Papp E; Steib A; Abdelwahab EM; Meggyes-Rapp J; Jakab L; Smuk G; Schlegl E; Moldvay J; Sárosi V; Pongracz JE
BMJ Open Respir Res; 2020 Jun; 7(1):. PubMed ID: 32527872
[TBL] [Abstract][Full Text] [Related]
18. Review: Cell Dynamics in Malignant Pleural Effusions.
Giarnieri E; Bellipanni G; Macaluso M; Mancini R; Holstein AC; Milanese C; Giovagnoli MR; Giordano A; Russo G
J Cell Physiol; 2015 Feb; 230(2):272-7. PubMed ID: 25205557
[TBL] [Abstract][Full Text] [Related]
19. Intrapleural urokinase for the treatment of loculated malignant pleural effusions and trapped lungs in medically inoperable cancer patients.
Hsu LH; Soong TC; Feng AC; Liu MC
J Thorac Oncol; 2006 Jun; 1(5):460-7. PubMed ID: 17409900
[TBL] [Abstract][Full Text] [Related]
20. New tools for old drugs: Functional genetic screens to optimize current chemotherapy.
Gerhards NM; Rottenberg S
Drug Resist Updat; 2018 Jan; 36():30-46. PubMed ID: 29499836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
